Blog
RSS FeedPosted by Michael Wonder on 20 Dec 2025
Eli Lilly cuts price of diabetes, weight loss drugs in Canada
17 December 2025 - Eli Lilly is slashing the prices of its popular diabetes and weight loss drugs Mounjaro and ...
Posted by Michael Wonder on 09 Dec 2025
Saskatchewan adds Capvaxive to publicly funded adult immunisation program
8 December 2025 - Merck announced today that the province of Saskatchewan has added Capvaxive, a 21 valent pneumococcal conjugate vaccine, ...
Posted by Michael Wonder on 06 Dec 2025
New resource: understanding Canada’s drug approval and reimbursement pathway
3 December 2025 - Understanding how new oncology and non-oncology drugs move through Canada’s regulatory and drug access pathways can ...
Posted by Michael Wonder on 05 Dec 2025
New data on drug approvals and reimbursement recommendations in Canada
27 November 2025 - We have published new data about Canada’s pharmaceutical landscape, including data about drug submissions filed with ...
Posted by Michael Wonder on 21 Nov 2025
Merck Canada and the pan-Canadian Pharmaceutical Alliance successfully complete negotiations for Winrevair (sotatercept)
20 November 2025 - Merck announced that it has successfully completed negotiations with the pan‑Canadian Pharmaceutical Alliance (pCPA) for Winrevair (sotatercept). ...
Posted by Michael Wonder on 09 Nov 2025
Rhythm Pharmaceuticals announces public reimbursement for Imcivree (setmelanotide) in Canada in five provinces and under the Federal Non-Insured Health Benefits Program
5 November 2025 - Rhythm Pharmaceuticals today announced that it has entered into Product Listing Agreements in the provinces of Ontario, ...
Posted by Michael Wonder on 07 Nov 2025
Rezurock now covered in Quebec for people living with chronic graft versus host disease
6 November 2025 - Sanofi is pleased to announce that Quebec has added Rezurock (belumosudil tablets) to the list of medications ...
Posted by Michael Wonder on 17 Oct 2025
Health Economics Methods Advisory Group releases draft report: asssessing treatment benefits in health technology assessment decision-making
9 October 2025 - Public comment period now open until 30 October 2025. ...
Posted by Michael Wonder on 19 Sep 2025
Biocon Biologics' Yesafili (aflibercept) now publicly funded in Ontario, Canada for the advanced treatment of patients with retinal diseases
18 September 2025 - -- Biocon Biologics is pleased to announce that Yesafili (aflibercept), a biosimilar to Eylea (aflibercept) injection, ...
Posted by Michael Wonder on 16 Sep 2025
The use of real world evidence among health care payers: a scoping review
12 September 2025 - Real world evidence is increasingly used to assess and make regulatory decisions on health technologies. However, its ...
Posted by Michael Wonder on 16 Sep 2025
AbbVie's Vraylar (cariprazine) now publicly reimbursed in Alberta
15 September 2025 - AbbVie announced today that Alberta has listed Vraylar (cariprazine) on its Health Drug Formulary. ...
Posted by Michael Wonder on 10 Sep 2025
Enhanced access to generalised myasthenia gravis treatments: UCB Canada secures pCPA agreements for Zilbrysq and Rystiggo
9 September 2025 - Important milestone brings eligible Canadians living with generalised myasthenia gravis one step closer to accessing innovative ...
Posted by Michael Wonder on 10 Sep 2025
Pfizer's Prevnar 20 selected for pneumococcal public immunisation program in British Columbia
9 September 2025 - Today, Pfizer Canada announced that its 20 valent pneumococcal conjugate vaccine, Prevnar 20, has been selected for ...
Posted by Michael Wonder on 31 Aug 2025
Vabysmo (faricimab injection) now publicly funded for macular oedema secondary to retinal vein occlusion in Ontario
29 August 2025 - Roche Canada is pleased to announce today that Vabysmo (faricimab injection) is now publicly funded for ...
Posted by Michael Wonder on 22 Aug 2025
Leqvio advances toward broader access with agreement between Novartis and the pan-Canadian Pharmaceutical Alliance
21 August 2025 - Eligible Canadian patients with heterozygous familial hypercholesterolaemia are one step closer to publicly funded access to ...